hotspot -WSS

hotspot

author：entertainment 2025-09-29 23:12:15 - browse：7547

The Johnson and Johnson booth at ESMO in Madrid. — The Johnson & Johnson booth at ESMO 2023. Andrew Joseph/STAT

MADRID — A competition has been brewing between two pharma titans — Johnson & Johnson and AstraZeneca — to gain an edge in the market for targeted lung cancer treatments. A primetime presentation here Monday amounted to the latest salvo.

At the annual meeting of the European Society for Medical Oncology, J&J unveiled three studies of its drug Rybrevant in different patient groups with non-small cell lung cancer with EGFR mutations. All were successful, with the drug, sometimes used in combination with other therapies, helping stave off progression of the disease.

In an interview, Mark Wildgust, J&J’s vice president of global medical affairs for oncology, framed the totality of the research as a case that Rybrevant could become a regularly used treatment for these patients.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： The real point of Kenneth Smith’s execution by nitrogen gas

knowledge

WSS

Vertex non

Personalized medicine goes far beyond genetics

Juul spent big to court Black leaders to promote its e

Congressmen charge Covid hearing ‘could have been an email’

Even great ERs can’t make up for American health disparities

2 officers injured in shooting in Orlando, police say

explore

hotspot

entertainment

Medical records are filled with copy

FDA scientists endorse Pfizer/BioNTech Covid

United colonoscopy coverage change 'may cost lives,' doctors say

Even great ERs can’t make up for American health disparities

Supreme Court strikes down use of affirmative action

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

ChatGPT in medicine: STAT answers readers' burning questions

The cancer stories no one wants to hear

Walensky prepares to leave CDC — and Congress — behind

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

Wikipedia

The lessons of Aduhelm, an Alzheimer's drug that was not to be

The cancer stories no one wants to hear

The a glaring gap in research on serious mental illness and primary care

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Do digital therapeutics have a future in medicine?

entertainment

knowledge

entertainment

explore